IL6 and neoplasm: Mechanistically, APS co-administration enhanced CD8+ T-cell infiltration, increased splenic and thymic indices, modulated cytokine profiles (TNF-α, IL-2, IFN-γ, IL-12, IL-6, IL-10), and reduced PD-1/PD-L1 expression in tumor tissue.